HSV1-HF10 VIRUS THERAPY FOR HEAD-AND-NECK CANCER

Disclosed is a method for treating human head-and-neck cancer by using a herpes simplex virus mutant having inactivated UL56 gene. Also disclosed is a pharmaceutical composition for use in this method. Preferably, the herpes simplex virus mutant is herpes simplex virus type 1 strain HF10. A clinical...

Full description

Saved in:
Bibliographic Details
Main Authors NISHIYAMA, YUKIHIRO, GOSHIMA, FUMI, NAKASHIMA, TSUTOMU, FUJIMOTO, YASUSHI, MIZUNO, TERUKAZU
Format Patent
LanguageEnglish
French
Japanese
Published 02.11.2006
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed is a method for treating human head-and-neck cancer by using a herpes simplex virus mutant having inactivated UL56 gene. Also disclosed is a pharmaceutical composition for use in this method. Preferably, the herpes simplex virus mutant is herpes simplex virus type 1 strain HF10. A clinical trial for study purposes is made on a patient with head-and-neck cancer by inoculating the pharmaceutical composition comprising attenuated herpes simplex virus to the patient at a subcutaneous tumor site. As a result, it is confirmed that the virus can produce an anti-tumor effect without adversely affecting the patient. L'invention concerne un procédé permettant de traiter le cancer humain de la tête et du cou en utilisant un virus mutant de l'herpès simplex présentant le gène UL56 sous forme inactivée. L'invention concerne également une composition pharmaceutique utilisée dans ce procédé. Le virus mutant de l'herpès simplex est de préférence un virus de l'herpès simplex de type 1 et de souche HF10. Un essai clinique est effectué, dans le cadre d'une étude, sur un patient atteint du cancer de la tête et du cou en lui inoculant sur un site tumoral sous-cutané la composition pharmaceutique renfermant une version atténuée du virus de l'herpès simplex. Il est ainsi prouvé que le virus peut produire un effet anti-tumoral sans provoquer d'effets secondaires chez le patient.
Bibliography:Application Number: WO2006JP308317